此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Nurse-led Structured Risk Factor Management Programme to Improve Quality of Life for Patients With Atrial Fibrillation

2026年11月4日 更新者:Chan Wai Ping、The University of Hong Kong

Effects of a Nurse-led Structured Risk Factor Management Programme on Health-related Quality of Life, Symptom Burden and Cardiovascular Health in Patients With Atrial Fibrillation: A Randomised Controlled Trial

The goal of this clinical trial is to evaluate the effects of a nurse-led, structured risk factor management programme on health-related quality of life, symptom burden and cardiovascular health in adults with atrial fibrillation (AF).

AF is the most common heart rhythm disorder. It increase the risk of stroke, heart failure, and death. Its symptoms, including palpitation, fatigue, and breathlessness, often limit daily activities and reduce quality of life, even in patients receiving treatment to control heart rhythm or rate. in the proposed nurse-led program, the cardiac nurse will teach AF patients how to manage health habits that affect AF, including eating well, staying active, sleeping well, not smoking, drinking less alcohol, and taking medicines as prescribed. A nurse works with each person to set small, realistic goals.

The main questions it aims to answer are:

  1. Does the programme improve health-related quality of life for AF patients?
  2. Does the programme improve symptom burden for AF patients?
  3. Does the programme improve the functional exercise capacity for AF patients?
  4. Does the programme increase the reported self-efficacy level for participants?
  5. Does the programme improve the health behaviours, physiological risk parameters and cardiovascular health score for participants?

Researcher will compare interventional group (80 AF participants joining the 12-week program in addition to usual care) to a control group (80 AF participants receive usual care only) to see if the program works to improve the quality of life, symptom burden and overall cardiovascular health than usual care alone among AF patients.

Participants in the intervention group will:

  1. Receive a 1-hour face-to-face individual session with nurse for structured AF self-management education and personalized behavioural change planning in week 1
  2. Keep track of their own health behaviours using a self-management booklet
  3. Get 6 bi-weekly telephone follow-up calls from the nurse to review progress and support staged behavioural change
  4. Receive weekly tailored text messages with reminders and encouragement

The study will take place at three hospitals in Hong Kong and will enrol about 160 adults. Each person will take part for about 5 months. Researchers will evaluate outcome (quality of life, AF symptom severity, functional exercise capacity, self-efficacy, health behaviours, body mass index, blood pressure, blood cholesterol, blood sugar, Life Essential 8 score) at three timepoint: baseline, upon completion of the programme (12 week), and 8 weeks thereafter (20 week).

研究概览

详细说明

Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. It increase the risk of stroke, heart failure, and death. Its symptoms, including palpitation, fatigue, and breathlessness, often limit daily activities and reduce quality of life, even in patients receiving treatment to control heart rhythm or rate. Comorbidity and risk factor contribute to the onset and progression of AF. International guidelines now recommend managing comorbidity and risk factors as a core pillar of AF care. However, translation into routine practice remains sub-optimal, characterized by brief, unstructured lifestyle counselling. This study is an assessor-blinded, parallel-group randomised controlled trial aiming to evaluate the effects of a nurse-led, structured risk factor management program on health-related quality of life, symptom burden, and cardiovascular health in AF patients, thereby informing secondary prevention of AF.

This study will be conducted in the specialist outpatient clinics of the cardiac units of three regional hospitals in Hong Kong. Eligible participants are adults aged ≥18 years who are (1) referred for management of symptomatic AF at the specialist outpatient clinic, (2) community-dwelling, (3) in possession of a smartphone, and (4) with at least one risk factor (hypertension, diabetes mellitus; BMI ≥23kg/m2; waist circumference ≥100cm for males or ≥90cm for females; dyslipidaemia; obstructive sleep apnoea; active smoking; alcohol use >3 standard drinks per week; and physical inactivity ). The sample size was estimated for the primary outcome of HRQoL at T1. Informed by two comparable nurse-led behavioural interventions and anticipating a medium effect, 64 participants per arm are required to detect an effect size of 0.5 with 80% power at a two-sided 5% significance level (G*Power 3.1.9.7). Applying a pooled baseline standard deviation of 18.6 points reported in a comparable Hong Kong AF population, this detects a between-group difference of 9.3 points on the primary HRQoL instrument, exceeding the 5-point minimal clinically important difference. Allowing for 20% attrition, 160 participants (80 per group) will be recruited. Participants will be randomly allocated in a 1:1 ratio to the intervention group (12-week nurse-led risk factor management programme in addition to usual care) or control group (usual care only).

Evaluation outcomes will be measured at baseline (T0), 12 weeks (T1), and 20 weeks (T2) thereafter. The primary outcome is health-related quality of life. Secondary outcomes include AF symptom severity, functional exercise capacity (distance walked in 6 minutes), self-efficacy, health behaviours (diet, physical activity, smoking status, sleep duration, alcohol consumption, and medication adherence), physiological parameters (body mass index, blood pressure, fasting lipid profile and fasting blood glucose), and overall cardiovascular health measured by the American Heart Association's Life Essential 8 score.

After double data entry, outcome analyses will be performed on an intention-to-treat basis. Normality of continuous variables will be assessed using the Shapiro-Wilk test to guide the choice between parametric and non-parametric methods. Baseline characteristics will be summarised as mean ± SD or median (IQR) for continuous variables and as frequencies and percentages for categorical variables, with baseline between-group homogeneity assessed using the independent t-test, chi-square test, or Mann-Whitney U test as appropriate. Primary analyses will employ generalised estimating equations (GEE) to examine between-group change across T0, T1, and T2, incorporating group and time as interaction terms and adjusting for a priori covariates (age, sex, AF type, AF duration, left atrial size, and left ventricular ejection fraction). Analyses will use IBM SPSS version 29.0, with a two-sided p-value < 0.05 considered statistically significant.

研究类型

介入性

注册 (估计的)

160

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Hong Kong、香港
        • Princess Margaret Hospital, Prince of Wales Hospital and Tuen Mun Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Chinese adults aged ≥18 years who are referring for management of symptomatic paroxysmal or persistent AF at the specialist outpatient clinics
  2. Community-dwelling
  3. Possessed a smartphone
  4. Has the presence of at least one of the following risk factors: hypertension, diabetes mellitus; BMI ≥23kg/m2; waist circumference ≥100cm for males or ≥90cm for females; dyslipidaemia; obstructive sleep apnoea; active smoking; alcohol use >3 standard drinks per week; and physical inactivity (i.e. <150 minutes of moderate-to-vigorous physical activity per week, or an average of <8000 steps per day)

Exclusion Criteria:

  1. Cannot understanding Cantonese or reading Chinese,
  2. Has impaired communication
  3. Has psychiatric problems
  4. Has cognitive impairment (i.e. Abbreviated Mental Test ≤6)
  5. Has severe co-existing medical conditions (e.g. terminal illness).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention group

The participants in the intervention group will receive a 12-week, structured, nurse-led risk factor management program for AF, in addition to the usual care at the study hospital.

This program, grounded in the Information-Motivation-Behavioral Skills model and Social Cognitive Theory, is designed to improve AF self-management and support sustained modification of behavioral risk factors . Delivered by a registered nurse with cardiac specialty, this program comprises 4 components:

  1. A 60-minute face-to-face individual session delivered in week 1 for risk profile assessment, AF self-management education, and personalized behavioral change planning
  2. Self-monitoring via self-management booklet, checklist, or smartphone step tracking according to participants' preference and capability, with progress reviewed at each contact
  3. 6 bi-weekly telephone follow-up calls (Weeks 2, 4, 6, 8, 10, 12) on stages of behavioral change: behavioral initiation, early problem-solving, behavioral consolidation, behavioral maintenance, relapse prevention and transition to self-management
  4. Weekly text messages sustaining participant's engagement with agreed behavioral goals.
无干预:Control group

The participants in the control group will receive the usual care provided by study hospital, comprising physician consultations and medication prescription at routine follow-up, without a structured risk factor management programme.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Health-related quality of life assessed by Atrial Fibrillation Effect on Quality-of-Life (AFEQT)
大体时间:At baseline, 12 weeks and 20 weeks

The 20-item AFEQT will be used to measure disease-specific health-related quality of life across four subscales: symptoms, daily activities, treatment concerns and treatment satisfaction. Each item is rated on a 7-point Likert scale. Raw scores are transformed to a 0-100 scale, with higher scores indicating better health status.

At baseline, 12 weeks and 20 weeks

次要结果测量

结果测量
措施说明
大体时间
AF symptom severity assessed by Atrial Fibrillation Severity Scale (AFSS)
大体时间:At baseline, 12 weeks and 20 weeks

The 19-item AFSS will be used to assess patient-perceived AF symptom burden and severity. The instrument comprises two items on demographic characteristics, five items on AF disease burden (the frequency, overall severity and duration of symptomatic AF episodes), one item on global well-being, four items on AF-related healthcare utilization, and seven items on AF symptom severity. The seven AF symptom severity items are rated on a five-point Likert scale, yielding a total AFSS severity score ranging from 0 to 35, with higher scores indicating more severe symptoms.

At baseline, 12 weeks and 20 weeks
Functional exercise capacity assessed by 6-minute Walk Test
大体时间:At baseline, 12 weeks and 20 weeks

The total distance walked in 6-minute walk test will be used to measure functional exercise capacity. Participants will be instructed to walk at their own pace along an uninterrupted 30-m corridor for 6 minutes with continuous heart rate monitoring. A longer distance indicates better functional exercise capacity.

At baseline, 12 weeks and 20 weeks
Self-efficacy assessed by General Self-Efficacy Scale (GSE)
大体时间:At baseline, 12 weeks and 20 weeks

A 10-item GSE will be used to measure individual's perceived capability to cope with stressful or challenging situations. This scale was commonly used to predict individual's behaviour, goal intentions and self-regulatory commitments, which are central in health promotion. Each item on a 4-point Likert scale and summed, with higher score indicating greater self-efficacy.

At baseline, 12 weeks and 20 weeks
Health behaviour: Dietary pattern assessed by Mediterranean Diet Scale (MDS) Questionnaire
大体时间:At baseline, 12 weeks and 20 weeks

A 13-item MDS Questionnaire will be used to assess self-reported adherence to Mediterranean dietary pattern. Each item is rated dichotomously (yes/ no) and summed, with higher score indicating greater adherence.

At baseline, 12 weeks and 20 weeks
Health behaviour: Physical activity level assessed by International Physical Activity Questionnaire-short form (IPAQ-SF)
大体时间:At baseline, 12 weeks and 20 weeks

The 7-item IPAQ-SF will be used to measure self-reported physical activity over the past week across four domains: vigorous activities, moderate activities, walking and sitting.68 Scores are expressed in metabolic equivalent of task (MET)-minutes per week, where higher values indicate higher energy expenditure.

At baseline, 12 weeks and 20 weeks
Health behaviour: Smoking status
大体时间:At baseline, 12 weeks and 20 weeks

Smoking status will be assessed by self-reporting cigarette use

At baseline, 12 weeks and 20 weeks
Health behaviour: Sleep duration
大体时间:At baseline, 12 weeks and 20 weeks

Sleep duration will be assessed by self-reporting average hours of sleep per night

At baseline, 12 weeks and 20 weeks
Health behaviour: Alcohol consumption level assessed by Alcohol Use Disorders Identification Test- Concise (AUDIT-C)
大体时间:At baseline, 12 weeks and 20 weeks

The 3-item AUDIT-C, a concise version of AUDIT, will be used to assess self-reported alcohol use across frequency of use, quantity of use, and frequency of health drinking. Each item is scored from 0 to 4 points, yielding a total score 0-12 with higher scores indicating greater alcohol use.

At baseline, 12 weeks and 20 weeks
Health behaviour: Medication adherence assessed by Medication Adherence Report Scale (MARS-5)
大体时间:At baseline, 12 weeks and 20 weeks

The 5-item MARS-5 will be used to assess self-reported unintentional and intentional medication adherence. Each item is rated on a 5-point Likert scale and summed, with higher score indicating better adherence.

At baseline, 12 weeks and 20 weeks
Physiological risk parameter: Body mass index
大体时间:At baseline, 12 weeks and 20 weeks

Body mass index will be calculated as dividing body weight (kilogram) by body height (meter) squared . Body weight and height are measured by a calibrated scale and stadiometer respectively.

At baseline, 12 weeks and 20 weeks
Physiological risk parameter: Systolic and diastolic blood pressure
大体时间:At baseline, 12 weeks and 20 weeks

Systolic and diastolic blood pressure will be measured using a digital automatic blood pressure monitor with an appropriate size cuff. Participants will be asked to relax and sit quietly for 3-5 minutes before the blood pressure measurement. They will be seated with their arm supported at heart level for the measurement.

At baseline, 12 weeks and 20 weeks
Physiological risk parameter: Fasting blood glucose
大体时间:At baseline, 12 weeks and 20 weeks

A fasting blood glucose will be assessed by a validated point-of-care device (BioHermes GluCoA1c) using a capillary blood sample obtained from a finger stick after 8 hours of fasting.

At baseline, 12 weeks and 20 weeks
Physiological risk parameter: Fasting lipid profile
大体时间:At baseline, 12 weeks and 20 weeks

A portable point-of-care analyser (VivaDiag Lipid Testing System) will be used to measure circulating cholesterol (total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides [TG]). Approximately 10uL of capillary blood sample will be collected at each measurement.

At baseline, 12 weeks and 20 weeks
Life's Essential 8 (LE8) Composite Score
大体时间:At baseline, 12 weeks and 20 weeks

LE8 is a cardiovascular health score. It comprises 8 components: diet (MDS score) , physical activity (minute of moderate-intensity activity per week), nicotine exposure (self-reported use of cigarettes), sleep health (average hours of sleep per night), body mass index (kilogram/ meter^2), blood lipids (non-HDL cholesterol), blood glucose (fasting blood glucose or HbA1c for diabetes) and blood pressure (systolic and diastolic blood pressure). Each LE8 components are scored on a scale of 0 to 100 points, allowing generation of a composite cardiovascular health score which is the unweighted average of all components. Total scores range from 0 to 100 points. Higher scores correspond to better cardiovascular health.

At baseline, 12 weeks and 20 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月16日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2026年11月4日

首先提交符合 QC 标准的

2026年11月4日

首次发布 (实际的)

2026年11月10日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIRB-2026-557-5
  • 2026.572 (其他标识符:The Joint CUHK-NTEC Clinical Research Ethics Committee)
  • HKWC-2026-527 (其他标识符:Institutional Review Board of HKU/ HA HKW)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅